Furthermore, mechanistic insights revealed that aleplasinin-mediated inhibition of PAI1 not only inhibited cell migration but also sensitised HER2-positive breast cancer cells to trastuzumab, suggesting a dual benefit of overcoming resistance and enhancing drug efficacy. The gene discussed is ERBB2; the disease is breast cancer.